ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025
Evaluation of Olanzapine for the Prevention of Refractory Chemotherapy-Induced Vomiting in Pediatric Oncology Patients.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of high-risk age groups for cisplatin-induced nausea and vomiting in young patients with sarcoma.Journal of pharmaceutical health care and sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe use of olanzapine for control of chemotherapy-induced vomiting (CIV) has increased; however, data on safety and efficacy in pediatric patients are limited. The primary objective of this study is to assess olanzapine for the prevention of refractory CIV in pediatric oncology patients.
methodsThis study is a retrospective, cross-control study of patients admitted to a pediatric hematology oncology service. Complete control of CIV was defined as no documented emesis and no administration of rescue antiemetics. For inclusion, patients had to have 1 encounter without and 1 encounter with olanzapine. Exclusion criteria included olanzapine use outside of CINV indication or olanzapine administration occurring after the start of chemotherapy.
resultsA total of 26 patients were included, with a median age of 14 years (IQR, 11.74-15.26) and median baseline weight of 56.2 kg (53.35-68.83). The median olanzapine dose administered was 0.089 mg/kg/dose. Olanzapine administration resulted in a higher number of patients achieving complete control of CIV (30.7% vs 11.5%; p = 0.001), reduction in doses of rescue antiemetic agents administered (1 vs 3 doses; p = 0.0117), but increase in documented somnolence by nurse assessment in patients receiving olanzapine (15.4% vs 7.7%; p < 0.001).
conclusionThe addition of olanzapine appears effective at achieving complete control of CIV when used for the prevention of refractory CIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.